Reference : Patients' preferences for anti-osteoporosis drug treatment: A cross-European discrete...
Scientific journals : Article
Human health sciences : General & internal medicine
http://hdl.handle.net/2268/220598
Patients' preferences for anti-osteoporosis drug treatment: A cross-European discrete choice experiment
English
Hiligsmann, M. [Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, Netherlands]
Dellaert, B. G. [Department of Business Economics, Erasmus School of Economics, Erasmus Rotterdam University, Rotterdam, Netherlands]
Dirksen, C. D. [Department of Clinical Epidemiology and Medical Technology Assessment, CAPHRI, Maastricht University, Maastricht, Netherlands]
Watson, V. [Health Economics Research Unit, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom]
Bours, S. [Department of Internal Medicine, Maastricht University Medical Centre, CAPHRI, Maastricht, Netherlands]
Goemaere, S. [Department of Rheumatology and Endocrinology, Ghent University Hospital, Gent, Belgium]
Reginster, Jean-Yves mailto [Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé >]
Roux, C. [Department of Rheumatology, Paris Descartes University, Paris, France]
McGowan, B. [The North Western Rheumatology Unit, Our Lady's Hospital, Manorhamilton, Co Leitrim, Ireland]
Silke, C. [The North Western Rheumatology Unit, Our Lady's Hospital, Manorhamilton, Co Leitrim, Ireland]
Whelan, B. [The North Western Rheumatology Unit, Our Lady's Hospital, Manorhamilton, Co Leitrim, Ireland]
Diez-Perez, A. [Musculoskeletal Research Unit and RETICEF, Universitat Autònoma de Barcelona, Barcelona, Spain]
Torres, E. [Musculoskeletal Research Unit and RETICEF, Universitat Autònoma de Barcelona, Barcelona, Spain]
Papadakis, G. [Service of Endocrinology, Diabetology and Metabolism, CHUV, Lausanne University Hospital, Lausanne, Switzerland]
Rizzoli, R. [Division of Bone Diseases, Geneva University Hospitals, Geneva, Switzerland]
Cooper, C. [MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, United Kingdom]
Pearson, G. [MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, United Kingdom]
Boonen, A. [Department of Internal Medicine, Maastricht University Medical Centre, CAPHRI, Maastricht, Netherlands]
2017
Rheumatology
Oxford University Press
56
7
1167-1176
Yes (verified by ORBi)
International
1462-0324
1462-0332
[en] Cross-country comparison ; Discrete choice experiment ; Drug treatment ; Osteoporosis ; Patients ; Preferences ; Article ; Belgium ; European ; France ; Ireland ; Likert scale ; Netherlands ; Spain ; Switzerland ; United Kingdom ; Europe ; Osteoporotic Fractures ; Absorptiometry, Photon ; Administration, Oral ; Aged ; Attitude to Health ; Belgium ; Bone Density Conservation Agents ; Cross-Sectional Studies ; Europe ; Female ; France ; Humans ; Injections, Intravenous ; Internationality ; Ireland ; Logistic Models ; Male ; Middle Aged ; Netherlands ; Osteoporotic Fractures ; Patient Preference ; Risk Assessment ; Severity of Illness Index ; Spain ; Surveys and Questionnaires
[en] Objectives. To estimate the preferences of osteoporotic patients for medication attributes, and analyse data from seven European countries. Methods. A discrete choice experiment was conducted in Belgium, France, Ireland, the Netherlands, Spain, Switzerland and the UK. Patients were asked to choose repeatedly between two hypothetical unlabelled drug treatments (and an opt-out option) that varied with respect to four attributes: efficacy in reducing the risk of fracture, type of potential common side effects, and mode and frequency of administration. In those countries in which patients contribute to the cost of their treatment directly, a fifth attribute was added: out-of-pocket cost. A mixed logit panel model was used to estimate patients' preferences. Results. In total, 1124 patients completed the experiment, with a sample of between 98 and 257 patients per country. In all countries, patients preferred treatment with higher effectiveness, and 6-monthly subcutaneous injection was always preferred over weekly oral tablets. In five countries, patients also preferred a monthly oral tablet and yearly i.v. injections over weekly oral tablets. In the three countries where the out-of-pocket cost was included as an attribute, lower costs significantly contributed to the treatment preference. Between countries, there were statistically significant differences for 13 out of 42 attribute/level interactions. Conclusion. We found statistically significant differences in patients' preferences for anti-osteoporosis medications between countries, especially for the mode of administration. Our findings emphasized that international treatment recommendations should allow for local adaptation, and that understanding individual preferences is important if we want to improve the quality of clinical care for patients with osteoporosis. © The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved.
http://hdl.handle.net/2268/220598
10.1093/rheumatology/kex071

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Patients’ preferences for anti-osteoporosis drug treatment - a cross-European discrete choice experiment.pdfPublisher postprint258.13 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.